Upstream Bio Inc.
Overview
Upstream Bio is developing treatments for inflammatory diseases, focusing on severe respiratory diseases, and is advancing verekitug, an antagonist targeting the TSLP receptor, currently in clinical development.
Therapeutic areas
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to Upstream Bio Inc. in our records. Events are linked by company name and identifier, so this is not proof that none exist; check the FDA's own databases before relying on it.
Is this Upstream Bio Inc.?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.